Genetic thrombophylia and kidney


Cite item

Full Text

Abstract

Thrombophilia is defined as predisposition of the organism to thrombosis development. There are acquired and inherited thrombophilia; both of them are considered as risk factors for arterial, venous and microcirculatory thrombosis. Kidney disease in patients with a genetic polymorphism of coagulation factors are manifested as renal vein and artery thrombosis, and thrombosis of renal microvasculature - thrombotic microangiopathy. Combination of thrombotic microangiopathy and chronic glomerulonephritis further the disease progression due to progressive nephrosclerosis

References

  1. Балуда В.П., Балуда М.В., Деянов И.И. и др. Физиология системы гемостаза. М., 1995.
  2. Schafer A. Hypercoagulable states: molecular genetics to clinical practice. Lancet 1994;344:1739-1742.
  3. Lane D.A., Mannucci P.M., Bauer K.A. et al. Inherited thrombophilia. Part I Thromb Haemost 1996; 76: 651-662.
  4. Воробьев А.И. Гиперкоагуляционный синдром в клинике внутренних болезней. Доклад на заседании МГНОТ 12 ноября 2008 года. Московский доктор. Вестник Московского городского научного общества терапевтов. 2009; 3(92): 1, 4-5.
  5. Hoppe C., Matsunaga A. Pediatric thrombosis. Pediatric Clin of North America 2002; 49: 1257-1283.
  6. Кондратьев Я.Ю., Носиков В.В., Дедов И.И. Полиморфные генетические маркеры и сосудистые осложнения сахарного диабета // Проблемы эндокринологии 1998. № 44 (1). С. 43-51.
  7. Чухловин А.Б., Фезе Б, Зарайский М.И. и соавт. Гиперактивные гены и риск развития острой реакции "трансплантат против хозяина" при интенсивной терапии онкогематологических заболеваний // Вопросы гематологии, онкологии, иммунопатологии, педиатрии. 2003. № 2(1). С. 66-70.
  8. Lane D., Grant P. Role of hemostatic gene polymorphisms in venous and arterial thrombotic desease. Blood 2000; 95: 1517-1532.
  9. De Lange M., Snieder H., Ariens R. et al. The genetics of haemostasis: a twin study. Lancet 2001; 357 (9250): 101-105.
  10. Bertina R.M. Genetic approach to thrombophilia. Thromb Haemost 2001; 86: 92-99.
  11. Nachman R.L., Silverstein R. Hypercoagulable states. Ann.Intern. Med. 1993; 119:819-827.
  12. Whitemann T., Hassouna H.I. Hypercoagulable states. Hemat. Oncol. Clin. N. Am. 2000; 14: 1431-1448.
  13. Llach F. Hypercoagulability, renal vein thrombosis and other thrombotic complications of nephrоtic syndrome. Kidney Int. 1985; 28: 429-435.
  14. Rabelink T.J., Zwaginga J.J., Koomans H.A., et al. Thrombosis and hemostasis in renal desease. Kidney Int. 1994; 46:287-298.
  15. Rosendaal F.R. Risk factors for venous thrombotic disease. Thromb Haemost 1999; 82: 610-619.
  16. Salomon O., Steinberg D.M., Zivelin A., et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999; 19: 511-518.
  17. Miyakis S., Lockshin M.D., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
  18. Forastiero R., Martinuzzo M., Adamczuk Y. et al. The combination of thrombophilic genotypes is associated with definite antiphospholipid syndrome. Heamatol 2001; 86(7):735-741.
  19. Roubey RAS. Mechanisms of autoantibody-mediated thrombosis. Lupus 1998; 7:S114-S119.
  20. Козловская Н.Л. Тромбофилические состояния // Клиническая фармакология и терапия. 2003. № 12(1). С. 74-80.
  21. Cameron J.S. Coagulation and thromboembolic complications in the nephrotic syndrome. Adv Nephrol 1984; 13: 75-113.
  22. Rosenberg R.D., Aird W.C. Vascular-bed-specific hemostasis and hypercoagulable states. N. Engl. J. Med. 1999; 340: 1555-1564.
  23. Mitra D., Jaffe E.A., Weksler B. et al. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood 1997; 89:1224-1234.
  24. Amigo M.-C., Garcia-Torres R., Robles M., et al. Renal involvement in primary antiphospholipid syndrome. J Rheumatol 1992; 19: 1181-1185.
  25. Cacoub P., Wechsler B., Piette J.C., et al. Malignant hypertension in antiphospholipid syndrome without overt lupus nephritis. Clin Exp Rheumat 1993; 11(5): 479-485.
  26. Levine J.S., Rauch J. Renal involvement in the antiphospholipid syndrome. In: Rhematology and the kidney. Ed. by D. Adu, P. Emery, M. Madaio. Oxford University Press, 2001; 133-166.
  27. Nochy D., Daugas E., Droz D. et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 1999;10: 507-518.
  28. Nzerue C.M., Hewan-Lowe K., Pierangeli S., Harris E.N. "Black swan in the kidney": renal involvement in the antiphospholipid syndrome. Kidney Int. 2002; 62: 733-744.
  29. Piette J.C., Kleinknecht D., Bach J.-F. Renal manifestation in the antiphospholipid syndrome. In: Asherson R., Cervera R., Piette J.C., Schoenfeld Y. (eds.) The antiphospholipid syndrome. Boca Raton: CRC Press; 1996. 169-181.
  30. Sangle S.R., D'Cruz D.P., Jan W. et al. Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension. Ann Rheum Dis 2003; 62: 999-1002.
  31. Asherson R.A, Cervera R. Catastrophic antiphospholipid syndrome. Curr Opin Hematol. 2000; 7: 325-329.
  32. Raife T.J., Lentz S.R., Atkinson B.S. et al. Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. Blood 2002; 99: 437-442.
  33. Alioglu B., Ozyurek E., Tarcan A., et al. Heterozygous methylenetetrahydrofolate reductase 677C-T gene mutation with mild hyperhomocysteinemia associated with intrauterine iliofemoral artery thrombosis. Blood Coagulation Fibrinolysis 2006; 17:495-498.
  34. Sherman G.G., Munster M., Govendrageloo K. et al. Low molecular weight heparin in the successful treatment of a spontaneous aortic thrombosis in a neonate. Pediatr Hematol Oncol. 2000; 17(5): 409-413.
  35. Gong R., Liu Z., Chen Z., et al. Genetic variations in plasminogen activator inhibitor-1 gene and beta fibrinogen gene associated with glomerular microthrombosis in lupus nephritis and the gene dosage effect. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2002;19: 1-5.
  36. Bellomo R., Atkins R.C. Membranous nephropathy and thromboembolism: is prophylactic anticoagulation warranted? Nephron 1993; 6(3): 249-254.
  37. Asherson R.A., Lancham J.G., Hull R.G. et al. Renal vein thrombosis in systemic lupus erythematosus:association with the"lupus anticoagulant".Clin Exp Rheumatol 1984; 2: 75-79.
  38. Asherson R.A., Buchanan N., Baguleu E. et al. Postpartum bilateral renal vein thrombosis in the primary antiphospholipid syndrome. J Rheumatol. 1993; 20: 1268-1272.
  39. Glueck H.I., Kant K.S., Weiss M.A. et al. Thrombosis in systemic lupus erythematosus. Relation to the presence of circulating anticoagulants. Arch Intern Med 1985; 145: 1389-1395.
  40. Vianna J.L., Khamashta M.A., Ordi-Ros J. Comparison of the primary and secondary antiphospholipid syndrome: an European multicenter study of 131 patients. Am J Med 1994; 96: 3-9.
  41. Козловская Н.Л., Медведева Т.Ю., Мирошниченко Н.Г. и др. Тромбоз почечных вен при мембранозной нефропатии // Терапевтический архив. 2000. № 6. С. 71-73.
  42. Баранникова Е.И., Козловская Н.Л., Понкина О.Н. и др. Генетическая гипергомоцистеинемия как причина артериальных и венозных тромбозов у больного хроническим гломерулонефритом // Нефрология и диализ. 2008. Т. 10. № 3-4. С. 254-258.
  43. Godfrey T., Khamashta M.A., Hughes G.R.V. Antiphospholipid syndrome and renal artery stenosis. Q J Med 2000; 93: 127-129.
  44. Ostuni P.A., Lazzarin P., Pengo V. et al. Renal artery thrombosis and hypertension in a 13 year old girl with antiphospholipid syndrome. Ann Rheum Dis 1990; 49: 184-187.
  45. Remondino G.I., Mysler E., Pissano M.N. et al. A reversible bilateral renal artery stenosis in association with antiphospholipid syndrome. Lupus 2000; 9: 65-67.
  46. Rossi E., Sani C., Zini M. et al. Anticardiolipin antibodies and renovascular hypertension. Ann Rheum Dis 1992; 51: 1180-1181.
  47. Asherson R.A., Nobel C.E., Hughes G.R.V. Hypertension, renal artery stenosis and the "primary" antiphospholipid syndrome. J Rheumatol 1991; 18(9): 1413-1415.
  48. George J., Shoenfeld Y. The anti-phospholipid (Hughes) syndrome: a crossroads of autoimmunity and atherosclerosis. Lupus 1997; 6: 559-560.
  49. Matsuura E., Kobayashi K., Koike T., et al. Autoantibody-mediated atherosclerosis. Autoimmun Rev. 2002; 1(6): 348-53.
  50. Rosen R. Genetic predisposition to hyperhomocysteinemia: deficiency of methylentetrahydrofolate reductase (MTHFR). Thromb.Haemost. 1997; 78: 523-526.
  51. Welch G.N., Loscalso J. Homocysteine and atherothrombosis. N. Engl. J. Med. 1998; 338: 1042-1050.
  52. Den Heijer M., Koster T., Blom H. K., et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N.Engl.J.Med. 1996; 334: 759-762.
  53. Den Heijer M., Lewington S., Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005; 3: 292-299.
  54. Boushey C.J., Beresford S.A.A., Omenn G.S. et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA. 1995; 274: 1049-1057.
  55. Clarke R. Homocysteine-lowering trials for prevention of heart disease and stroke. Semin Vasc Med. 2005; 5: 215-222.
  56. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. J. Am. Med. Assoc. 2002; 288: 2015-2022.
  57. Graham I.M., Daly L.E., Refsum H.M. et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997; 277: 1775-1781.
  58. Harker L.A., Ross R., Slichter S.J, et al. Homocysteine-induced arteriosclerosis: the role of endothelial cell injury and platelet responce in its genesis. J. Clin. Invest. 1976; 58: 731-741.
  59. Fryer R.H., Wilson B.D., Gubler D.B. et al. Homocysteine, a risk factor for premature vascular disease and thrombosis, induced tissue factor activity in endothelial cells. Arterioscler. Thromb. 1993; 13: 1327-1333.
  60. Austin R.C., Lentz S.R., Werstuck G.H. Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Сеll Death Differ 2004; 11: S56-S64.
  61. Bellamy M.F., McDowell I.F., Ramsey M.W. Hyperhomocysteinemia after ап огаl methionine load acutely impairs endothelial function in healthy adults. Circulation 1998; 98: 1848-1852.
  62. Chambers J.C., McGregor D., Jean-Marie J. et al. Demonstration of rapid inset vascular endothelial dysfunction after hyperhomocysteinemia and effect reversibIe with vitamin С therapy. Circulation 1999; 99: 1156-1160.
  63. Sauls D.L., Lockhart E., Warren M.E. et al. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. Biochemistry, 2006; 45(8): 2480-2487.
  64. Perutelli P., Amato S., Minniti G. et al. Von Willebrand factor multimer composition is modified following oral methionine load in women with thrombosis, but not in healthy women. Blood Coagul Fibrinolysis. 2005; 16(4): 267-273.
  65. Lee R., Frenkel Е.Р. Hyperhomocysteinemia and thrombosis. Hematol Опcol Clin North Аm 2003; 17(1): 85-102.
  66. Welch G.N., Upchurch G.R.J., Loscalzo J. Homocysteine, oxidative stress, and vascular disease. Hosp Pract 1997; 32: 81-82.
  67. Tsai J.C., Perrella М.А., Yoshizumi М. et al. Promotion of vascular smooth muscle сеll growth bу homocysteine: а link to atherosclerosis. Рrос Natl Acad Sci USA 1994; 91: 6369-6373.
  68. Kluijtmans L.A.J., Whitehead A.S. Methylentetrahydrofolate reductase genotypes and predisposition to atherothrombotic disease. Eur Heart J 2001; 22: 294-299.
  69. Sherman G.G., Munster M., Govendrageloo K. et al. Low molecular weight heparin in the successful treatment of a spontaneous aortic thrombosis in a neonate. Pediatr Hematol Oncol. 2000; 17(5): 409-413.
  70. Queffeulou G., Michel C., Vrtovsnik F. et al. Hyperhomocysteinemia, low folate status, homozygous C677T mutation of the methylene tetrahydrofolate reductase and renal arterial thrombosis. Clinl Nephrol. 2002; 57(2):158-162.
  71. Сорокин Ю.Д., Николаева Т.С., Панасюк В.В. Множественные артериальные тромбозы у 52-летнего мужчины с наследственной тромбофилией, обусловленной гомозиготной мутацией гена метилентетрагидрофолатредуктазы, леченные комбини-рованной антикоагулянтной терапией. В кн. "Инновационные технологии и прогресс терапевтической клиники" / Под ред. Н.А. Мухина. М., 2008. С. 28-31.
  72. Козловская Н.Л., Котлярова Г.В., Боброва Л.А. и соавт. Двусторонняя окклюзия почечных артерий с восстановлением функции почек после длительной терапии программным гемодиализом у пациента с генетической формой тромбофилии // Нефрология и диализ. 2008. Т. 10. № 2. С. 151-159.
  73. Козловская Н.Л., Боброва Л.А., Захарова Е.В. и соавт. Двусторонний стеноз почечных артерий у больного первичным антифосфолипидным синдромом, перенесшего гемолитико-уремический синдром (описание случая и обзор литературы) // Терапевтический архив. 2008. № 6. С. 69-73.
  74. Asherson R.A. The catastrophic antiphospholipid syndrome. A review of the clinical features, possible patogenesis and treatment. Lupus 1998; 7: S55-S62.
  75. Daugas E., Nochy D., Thi Huong D.L. et al. Antiphospholupid syndrome nephropathy in systemic lupus erythematosus J. Am. Soc. Nephrol. 2002; 13: 42-52.
  76. Козловская Н.Л., Шилов Е.М., Метелева Н.А. и соавт. Клинико-морфологические особенности нефропатии при первичном и вторичном антифосфолипидном синдроме // Терапевтический архив. 2007. № 6. С. 16-25.
  77. Moss K.E., Isenberg D.A. Comparison of renal disease and outcome in patients with primary antiphospholipid syndrome, antiphospholipid syndrome secondary to systemic lupus erythematosus (SLE) and SLE alone. J. Rheumatol. 2001; 40: 863-867.
  78. Moake J.L. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
  79. Besbas N., Karpman D., Landau D. et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Intern 2006; 70:423-431.
  80. Rollino C., Mazzucco G., Boero R. et al. Is it possible to diagnose primary antiphospholipid syndrome (PAPS) on the basis of renal thrombotic microangiopathy (PAPS nephropathy) in the absence of orther thrombotic process? Ren Fail 2003; 25(6): 1043-1049.
  81. Lockshin M.D. Update on antiphospholipid syndrome. Bull NYU Hosp Joint Disease 2008; 66(3):195-197.
  82. Griffiths M.H., Papadaki L., Neild G.H. The renal pathology of primary antiphospholipid syndrome: a distinctive form of endothelial indjury. Quart J Med. 2000; 93: 457-467.
  83. Meroni P.L., Riboldi P. Pathogenetic mechanism mediating antiphospholipid syndrome. Curr Opin Rheumatology .2001; 13: 377-382.
  84. Forastiero R., Martinuzzo M. Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome. Lupus 2008;17:872-877.
  85. Козловская Н.Л., Фомин В.В., Пальцева Е.М. и соавт. 4G/4G мутация гена ингибитора активатора плазминогена типа 1 - причина острого коронарного синдрома и почечной тромботической микроангиопатии у молодого больного. В кн. "Инновационные технологии и прогресс терапевтической клиники" / Под ред. Н.А. Мухина. М., 2008. С. 17-20.
  86. Фомин В.В., Козловская Н.Л., Пальцева Е.М. и соавт. Наследственная тромбофилия - носительство ТТ677 варианта метилентетрагидрофолатредуктазы с гипергомоцистеинемией и 4G/4G варианта гена ингибитора активатора плазминогена типа 1 как ведущая причина почечной недостаточности и сердечно-сосудистых осложнений у молодого больного хроническим латентным гломерулонефритом. В кн. "Инновационные технологии и прогресс терапевтической клиники" / Под ред. Н.А. Мухина. М., 2008. С. 36-48.
  87. De Serres S.A., Isenberg P. Athrombocytopenic thrombotic microangiopathy, a condition that could be overlooked based on current diagnostic criteria. NDT advanced access, 2008.
  88. Калашникова Е.А., Кокаровцева С.Н., Коваленко Т.Ф. и соавт. Частоты мутаций в генах фактора V (FV Leiden), протромбина (G20210A) и 5,10-метилентетрагидрофолатредуктазы (C677T) у русских // Медицинская генетика. 2006. № 7. С. 27-29.
  89. Kant K.S., Pollak V.E., Weiss M.A. et al. Glomerular thrombosis in systemic lupus erythematosus: prevalence and significance. Medicine 1981; 60(7): 71-85.
  90. Caletti M.G., Gallo G., Gianantonio C.A. Development of focal segmental sclerosis and hyalinosis in haemolytic uremic syndrome. Pediatr Nephrol 1996; 10(6):687-692.
  91. Ruggenenti P., Remuzzi G. Malignant vascular disease of the kidney: nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy. Am. Journ Kidney Dis. 1996; 27: 459-475.
  92. Tectonidou M.G., Sotsiou F., Nakopoulou L. et al. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations and long-term outcome. Arthritis Rheum. 2004; 50(8): 2569-2579.
  93. Shanley P.F. The pathology of chronic renal ischemia. Semin Nephrol. 1996; 16(1): 21-32.
  94. Meyrier A. Vascular mechanisms of renal fibrosis. Vasculonephropathies and arterial hypertension. Bull Acad Natl Med. 1999; 183(1): 33-45.
  95. Nakagawa T., Kang D.H., Ohashi R. et al. Tubulointerstitial disease: role of ischemia and microvascular disease. Curr Opin Nephrol Hypertens. 2003; 12(3): 233-241.
  96. Fogo A. Mechanisms in nephrosclerosis and hypertension-beyond hemodinamics. J Nephrol 2001; 14 (Suppl. 4): S63-69.
  97. Futrakul N., Futrakul P. Renal microvascular disease in the aging population: a reversible process? Ren Fail. 2008; 30(4): 353-356.
  98. Goforth R.L., Rennke H., Sethi S. Renal vascular sclerosis is associated with inherited thrombophilias. Kidney Int 2006;70: 743-50.
  99. Marcantoni C., Fogo A.B. A perspective on arterionephrosclerosis: from pathology to potential pathogenesis. J. Nephrol. 2007; 20: 518-524.
  100. Koupepidou P., Deltas C., Christofides T.C. et al. The MHTFR 677TT and 677CT/128AC genotypes in Cypriot patients may be predisposing to hypertensive nephrosclerosis and chronic renal failure. Int Angiol 2005; 24: 287-294.
  101. Neugebauer S., Baba T., Watanabe T. Methylentetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in NIDDM patients. Lancet 1998; 352: 454-459.
  102. Moszulski D., Fojcik H., Zukowska-Szczechowska E., et al. Effect of the C677T and A1298C polymorphism of the MTHFR gene on the genetic predisposition for diabetic nephropathy. Nephrol Dial Transplant 2003; 18: 1535-1540.
  103. Suzuki H., Sakuma Y., Kanesaki Y. et al. Close relationship of plasminogen activator inhibitor-1 4G/5G polymorphism and progression of IgA nephropathy. Clin nephrol 2004; 62:173-179.
  104. Cheng-Hsu C., Kuo-Hsiung S., Mei-Chin W. et al. Impact of plasminogen activator inhibitor-1 gene polymorphismson primary membranous nephropathy. Nephrol Dial Transplant 2008;23:3166-3173.
  105. Gong R., Liu Z., Li L. Epistatic effect of plasminogen activator inhibitorI and β-fibrinogen genes on risk of glomerular microthrombosis in lupus nephritis. Arthritis Rheum 2007; 56:1608-1617.
  106. Segui R., Estelles A., Mira Y. et al. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Brit J Haematol 2000; 111: 122-128.
  107. Tassies D., Espinosa G., Munos-Rodriges F.J. et al. The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum 2000; 43(10): 2349-2358.
  108. Sofi F., Lari B., Rogolino A. et al. Thrombophilic risk factors for symptomatic peripheral arterial disease. J Vasc Surg 2005; 41: 255-260.
  109. Андреенко Г.В., Полянцева Л.Р., Подорольская Л.В. Фибринолитические свойства плазмы крови, мочи и отечных жидкостей у больных с нефротическим синдромом // Терапевтический архив. 1982. № 7. С. 53-57.
  110. Козловская Л.В., Бобкова И.Н., Плиева О.К. и др. Значение исследования в моче молекулярных медиаторов иммунного воспаления и фиброза в почке при хроническом гломерулонефрите // Терапевтический архив. 2004. № 9. С. 84-87.
  111. Hamano K., Iwano M., Akai Y., et al. Exspression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis. 2002; 39: 695-705.
  112. Yi F., Li P.L. Mechanisms of homocysteine-induced glomerular injury and sclerosis. Am J Nephrol. 2008; 28(2): 254-264.
  113. Fogo A. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis. 2000; 35(2): 179-188.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies